Carcinoembryonic antigen autologous dendritic cell vaccine (Duke University)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameCarcinoembryonic antigen autologous dendritic cell vaccine (Duke University)
Drug Alias NameCEA RNA transfected autologous dendritic cell vaccine树突状细胞疫苗-杜克大学
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 agonists
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsNeoplasm MetastasisLung NeoplasmsHead and Neck Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDuke University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDuke UniversityDuke Cancer Institute
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisLung NeoplasmsHead and Neck Neoplasms +[12] 

Other Information

ATC CodeN/A
Related LinksN/A